-
Mali junta in crisis after minister killed, key city 'captured'
-
Dortmund down Freiburg to seal Champions League spot
-
McFarlane hails Chelsea 'character' after FA Cup semi-final win
-
Gunman sought to kill Trump, cabinet at gala dinner
-
Arsenal punish Lyon errors in Champions League semi
-
Suspect in US press gala shooting - what we know
-
Key US senator lifts block on Fed chair nominee
-
Attacks in Mali: What we know
-
Vollering wins women's Lige-Bastogne-Liege for 3rd time
-
Sinner motors on in Madrid as Gauff overcomes stomach bug
-
Fernandez sends Chelsea into FA Cup final to lift gloom after Rosenior sacking
-
Colombia road bombing death toll rises to 19
-
Stuttgart stumble against Bremen in top-four race
-
Two former Israel PMs unite to challenge Netanyahu in elections
-
Trump says shooting proves need for his White House ballroom
-
Pogacar cracks teen Seixas to win 4th Liege-Bastogne-Liege
-
Iran minister returns to Pakistan despite US talks cancellation
-
Rabada's 3-25 helps Gujarat thrash Chennai in IPL
-
Pogacar beats teen Seixas to win 4th Liege-Bastogne-Liege
-
Gunman planned to target top Trump officials: attorney general
-
Alex Marquez wins Spanish MotoGP to end Bezzecchi streak
-
History-maker Sawe shatters marathon glass ceiling
-
Gauff overcomes stomach bug to beat Cirstea in Madrid
-
Mali defence minister killed, fresh fighting between army and rebels
-
Sawe makes history with first sub-two-hour marathon in London
-
Assefa wins London Marathon in women's-only world record time
-
Superstar galloper Ka Ying Rising storms to 20th straight win
-
Austria's Wiesberger wins first DP World Tour title in 1,792 days
-
Cummins hails teen wonder Sooryavanshi as 'my new favourite player'
-
New fighting in Mali's Kidal between army and rebels
-
Chernobyl refugee town welcomes Ukraine's conflict displaced
-
World leaders react to Washington gala shooting
-
Zelensky accuses Russia of 'nuclear terrorism' on Chernobyl anniversary
-
Coach says 'glimmer of hope' for imperilled Moana Pasifika
-
'I've studied assassinations': Trump muses on reasons for latest shooting
-
What we know about the Trump press gala shooting
-
Al Ahli made to 'suffer' in winning Asian Champions League: coach
-
India plugs oil gap as Middle East supplies sink
-
Trump evacuated as shooter opens fire at Washington gala
-
'Get down!' Panic and chaos at glitzy media gala
-
Timberwolves' Edwards, DiVincenzo injured in playoff win over Nuggets
-
T'Wolves shake off key injuries to beat Nuggets for 3-1 series lead
-
Japan's Machida had 'mental pressure' in Champions League final loss
-
US Fed set to hold rates steady again on cost hikes from Mideast war
-
Trump evacuated as shooter opens fire at Washington gala event
-
Exiled Tibetans to elect government in vote condemned by China
-
Exiled Tibetans elect government in vote condemned by China
-
Japan inflation cools demand for vending machine drinks
-
Badminton eyes 'next generation' with new scoring system
-
Acid attacks highlight growing danger for Indonesian activists
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus.
Event: Q1 Investor Summit
Presentation Time: 11:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52091
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
Access Newswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESS Newswire
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Barinthus Biotherapeutics plc
View the original press release on ACCESS Newswire
L.Miller--AMWN